基于CiteSpace和VOSviewer软件分析老年患者静脉血栓栓塞症的文献计量学分析

doi:10.5246/jcps.2026.03.019

中国药学(英文版) ›› 2026, Vol. 35 ›› Issue (3): 275-291.DOI: 10.5246/jcps.2026.03.019

基于CiteSpace和VOSviewer软件分析老年患者静脉血栓栓塞症的文献计量学分析

陈晶晶¹^,^#, 鞠建杰¹^,^#, 王婧婷², 阳丽梅²^,^*()

^1. 福建医科大学药学院, 福建福州 350122
^2. 福建医科大学省立临床医学院/福建省立医院/福州大学附属省立医院药学部, 福建福州 350001

收稿日期:2025-11-18 修回日期:2025-12-23 接受日期:2026-01-14 出版日期:2026-04-04 发布日期:2026-04-03
通讯作者: 阳丽梅

Bibliometric analysis of venous thromboembolism in the elderly using CiteSpace and VOSviewer

Jingjing Chen¹^,^#, Jianjie Ju¹^,^#, Jingting Wang², Limei Yang²^,^*()

^1. School of Pharmacy, Fujian Medical University, Fuzhou 350122, Fujian, China
^2. Department of Pharmacy, Provincial Clinical College of Fujian Medical University/ Fujian Provincial Hospital/Fuzhou University Affiliated Provincial Hospital, Fuzhou 350001, Fujian, China

Received:2025-11-18 Revised:2025-12-23 Accepted:2026-01-14 Online:2026-04-04 Published:2026-04-03
Contact: Limei Yang
About author:
^# Jingjing Chen and Jianjie Ju contributed equally to this work.
Supported by:
the Natural Science Foundation of Fujian (Grant No. 2022J011011)

摘要/Abstract

摘要：

静脉血栓栓塞症(VTE)每年导致全球约一百万人死亡, 给医疗资源带来沉重负担。该疾病的发病率随年龄呈指数级增长, 相关危险因素在老年人群中尤为显著, 多种基础健康问题进一步增加了该群体的VTE发生风险。本研究通过Web of Science核心合集数据库, 检索2009年1月1日至2024年6月24日期间发表的老年VTE相关文献, 运用CiteSpace和VOSviewer软件对出版物、国家、机构、期刊、作者及关键词进行文献计量分析。共纳入15 437篇文献, 其中美国发文量居首, 哈佛大学是该领域研究实力最强的机构。值得注意的是, 挪威学者Rosendaal FR在老年VTE研究中贡献突出。《血栓与止血杂志》被认定为该领域最具影响力的期刊。关键词中心性与引文突现分析显示, 近期研究热点集中于老年VTE患者的药物治疗及预后评估。本研究系统梳理了截至2024年全球老年VTE研究态势, 揭示了新兴研究热点与发展趋势, 预示未来研究将聚焦于该高危人群的治疗策略与预防措施。

关键词: 文献计量学, 静脉血栓栓塞症, 老年人, 抗凝剂, 预防

Abstract:

Venous thromboembolism (VTE) remains a major global health concern, contributing to an estimated one million deaths annually and imposing a considerable strain on healthcare systems worldwide. Its incidence escalates dramatically with advancing age, with elderly individuals exhibiting heightened vulnerability due to the accumulation of comorbidities and age-related physiological changes. In the present study, we systematically analyzed research trends in VTE among older adults by mining the Web of Science Core Collection (WOSCC) for publications spanning January 1, 2009 to June 24, 2024. CiteSpace and VOSviewer were employed to map the scientific landscape, encompassing publication volume, geographical distribution, institutional output, authorship networks, and thematic evolution through keyword analysis. A total of 15 437 articles met the inclusion criteria. The United States emerged as the most prolific contributor, with Harvard University standing out as the leading research institution. Among individual researchers, Rosendaal FR of Norway was identified as a key thought leader in this domain. The Journal of Thrombosis and Haemostasis was recognized as the most influential publication outlet. Keyword centrality and citation burst analyses revealed that recent scholarly attention increasingly converged on pharmacologic interventions and outcome prediction in elderly VTE patients. This study provided a comprehensive overview of the global research trajectory on VTE in the aging population, highlighting shifting priorities and suggesting a future emphasis on optimizing therapeutic approaches and implementing robust preventive strategies for this high-risk demographic.

Key words: Bibliometrics, Venous thromboembolism, Elderly, Anticoagulant, Prophylaxis

Supporting:

陈晶晶, 鞠建杰, 王婧婷, 阳丽梅. 基于CiteSpace和VOSviewer软件分析老年患者静脉血栓栓塞症的文献计量学分析[J]. 中国药学(英文版), 2026, 35(3): 275-291.

Jingjing Chen, Jianjie Ju, Jingting Wang, Limei Yang. Bibliometric analysis of venous thromboembolism in the elderly using CiteSpace and VOSviewer[J]. Journal of Chinese Pharmaceutical Sciences, 2026, 35(3): 275-291.

图/表 9

Table 1. The search strategy of WOSCC.

Figure 1. The specific retrieval procedure.

Figure 2. The number of annual publications and citation frequency from 2009 to 2024.

Figure 3. Analysis of countries’ publications on VTE in the elderly. (A) The overlay visualization map among the top 40 countries and regions. Node size reflects document volume, and color indicates the year of publication; (B) The network map of country collaboration. Color intensity reflects the national publication volume, while the thickness and quantity of the tan line indicate the degree of cooperation; (C) Analysis of countries with ≥ 100 publications.

Figure 4. Analysis of institutions regarding VTE in the elderly. (A) The overlay visualization map of institutions with ≥ 50 publications. (B) The top 15 institutions in terms of citations and publication volume.

Table 2. The top 10 prolific authors. The H-index measures a scholar’s influence and output based on their publications and citations.

Figure 5. Co-authorship analysis of the excellent authors about VTE in the elderly. (A) The overlay visualization map of authors; (B) Countries and institutions of these distinguished authors.

Table 3. The top 10 of journals with the highest number of articles.

Figure 6. Analysis of keywords related to VTE in the elderly. (A) The visualization network map of keywords. A node represents a keyword, with its size reflecting the keyword’s frequency; (B) The top 25 keywords with the strongest citation burst. The blue bar represents the monitoring period, while the red bar denotes the duration of the burst keyword; (C) The timeline view of keywords with 12 main clusters.

参考文献 53

[1]	Raskob, G.E.; Angchaisuksiri, P.; Blanco, A.N.; Buller, H.; Gallus, A.; Hunt, B.J.; Hylek, E.M.; Kakkar, A.; Konstantinides, S.V.; McCumber, M.; Ozaki, Y.; Wendelboe, A.; Weitz, J.I. Thrombosis: a major contributor to global disease burden. Thromb. Res. 2014, 134, 931–938.
[2]	Wendelboe, A.M.; Raskob, G.E. Global burden of thrombosis: epidemiologic aspects. Circ. Res. 2016, 118, 1340–1347.
[3]	Cohen, A.T.; Agnelli, G.; Anderson, F.A.; Arcelus, J.I.; Bergqvist, D.; Brecht, J.G.; Greer, I.A.; Heit, J.A.; Hutchinson, J.L.; Kakkar, A.K.; Mottier, D.; Oger, E.; Samama, M.M.; Spannagl, M.; Impact Assessment Group in Europe (VITAE), V.T.E. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb. Haemost. 2007, 98, 756–764.
[4]	Silverstein, R.L.; Bauer, K.A.; Cushman, M.; Esmon, C.T.; Ershler, W.B.; Tracy, R.P. Venous thrombosis in the elderly: more questions than answers. Blood. 2007, 110, 3097–3101.
[5]	Poli, D.; Antonucci, E.; Testa, S.; Tosetto, A.; Ageno, W.; Palareti, G.; Italian Federation of Anticoagulation Clinics. Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. Circulation. 2011, 124, 824–829.
[6]	Spencer, F.A.; Gurwitz, J.H.; Schulman, S.; Linkins, L.A.; Crowther, M.A.; Ginsberg, J.S.; Lee, A.Y.Y.; Saczynski, J.S.; Anand, S.; Lessard, D.; Emery, C.; Huang, W.; Goldberg, R.J. Venous thromboembolism in older adults: a community-based study. Am. J. Med. 2014, 127, 530–537.e3.
[7]	Næss, I.A.; Christiansen, S.C.; Romundstad, P.; Cannegieter, S.C.; Rosendaal, F.R.; Hammerstrøm, J. Incidence and mortality of venous thrombosis: a population‐based study. J. Thromb. Haemost. 2007, 5, 692–699.
[8]	Spencer, F.A.; Gore, J.M.; Lessard, D.; Emery, C.; Pacifico, L.; Reed, G.; Gurwitz, J.H.; Goldberg, R.J. Venous thromboembolism in the elderly. A community-based perspective. Thromb. Haemost. 2008, 100, 780–788.
[9]	Tagalakis, V.; Patenaude, V.; Kahn, S.R.; Suissa, S. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE study cohort. Am. J. Med. 2013, 126, 832.e13–832.e21.
[10]	Palareti, G.; Poli, D. The prevention of venous thromboembolism recurrence in the elderly: a still open issue. Expert Rev. Hematol. 2018, 11, 903–909.
[11]	Johnson, S.A.; Eleazer, G.P.; Rondina, M.T. Pathogenesis, diagnosis, and treatment of venous thromboembolism in older adults. J. Am. Geriatr. Soc. 2016, 64, 1869–1878.
[12]	Beckman, M.G.; Hooper, W.C.; Critchley, S.E.; Ortel, T.L. Venous thromboembolism: a public health concern. Am. J. Prev. Med. 2010, 38, S495–S501.
[13]	Mulder, F.I.; Horváth-Puhó, E.; van Es, N.; van Laarhoven, H.W.M.; Pedersen, L.; Moik, F.; Ay, C.; Büller, H.R.; Sørensen, H.T. Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 2021, 137, 1959–1969.
[14]	Klok, F.A.; van der Hulle, T.; den Exter, P.L.; Lankeit, M.; Huisman, M.V.; Konstantinides, S. The post-PE syndrome: a new concept for chronic complications of pulmonary embolism. Blood Rev. 2014, 28, 221–226.
[15]	Ceriani, E.; Combescure, C.; LE GAL, G.; Nendaz, M.; Perneger, T.; Bounameaux, H.; Perrier, A.; Righini, M. Clinical prediction rules for pulmonary embolism: a systematic review and meta-analysis. J. Thromb. Haemost. 2010, 8, 957–970.
[16]	van der Hulle, T.; Cheung, W.Y.; Kooij, S.; Beenen, L.F.M.; van Bemmel, T.; van Es, J.; Faber, L.M.; Hazelaar, G.M.; Heringhaus, C.; Hofstee, H.; Hovens, M.M.C.; Kaasjager, K.A.H.; van Klink, R.C.J.; Kruip, M.J.H.A.; Loeffen, R.F.; Mairuhu, A.T.A.; Middeldorp, S.; Nijkeuter, M.; van der Pol, L.M.; Schol-Gelok, S.; Ten Wolde, M.; Klok, F.A.; Huisman, M.V.; study group, Y.E.A.R.S. Simplified diagnostic management of suspected pulmonary embolism (the YEARS study): a prospective, multicentre, cohort study. Lancet. 2017, 390, 289–297.
[17]	Wells, P.S.; Anderson, D.R.; Rodger, M.; Stiell, I.; Dreyer, J.F.; Barnes, D.; Forgie, M.; Kovacs, G.; Ward, J.; Kovacs, M.J. Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and d-dimer. Ann. Intern. Med. 2001, 135, 98–107.
[18]	Agnelli, G.; Buller, H.R.; Cohen, A.; Curto, M.; Gallus, A.S.; Johnson, M.; Porcari, A.; Raskob, G.E.; Weitz, J.I.; Investigators, A.E. Apixaban for extended treatment of venous thromboembolism. N. Engl. J. Med. 2013, 368, 699–708.
[19]	Schulman, S.; Kearon, C.; Kakkar, A.K.; Schellong, S.; Eriksson, H.; Baanstra, D.; Kvamme, A.M.; Friedman, J.; Mismetti, P.; Goldhaber, S.Z.; Investigators, R.T.; Investigators, R.T. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N. Engl. J. Med. 2013, 368, 709–718.
[20]	Bartholomew, J.R. Update on the management of venous thromboembolism. Cleve. Clin. J. Med. 2017, 84, 39–46.
[21]	Konstantinides, S.V.; Meyer, G.; Becattini, C.; Bueno, H.; Geersing, G.J.; Harjola, V.P.; Huisman, M.V.; Humbert, M.; Jennings, C.S.; Jiménez, D.; Kucher, N.; Lang, I.M.; Lankeit, M.; Lorusso, R.; Mazzolai, L.; Meneveau, N.; Áinle, F.N.; Prandoni, P.; Pruszczyk, P.; Righini, M.; Torbicki, A.; Van Belle, E.; Zamorano, J.L.; Scientific Document Group, E.S.C. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur. Heart J. 2020, 41, 543–603.
[22]	Giri, J.; Sista, A.K.; Weinberg, I.; Kearon, C.; Kumbhani, D.J.; Desai, N.D.; Piazza, G.; Gladwin, M.T.; Chatterjee, S.; Kobayashi, T.; Kabrhel, C.; Barnes, G.D. Interventional therapies for acute pulmonary embolism: current status and principles for the development of novel evidence: a scientific statement from the American heart association. Circulation. 2019, 140, e774–e801.
[23]	Stein, P.D.; Matta, F. Thrombolytic therapy in unstable patients with acute pulmonary embolism: saves lives but underused. Am. J. Med. 2012, 125, 465–470.
[24]	Keller, K.; Hobohm, L.; Ebner, M.; Kresoja, K.P.; Münzel, T.; Konstantinides, S.V.; Lankeit, M. Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany. Eur. Heart J. 2020, 41, 522–529.
[25]	Becattini, C.; Agnelli, G.; Lankeit, M.; Masotti, L.; Pruszczyk, P.; Casazza, F.; Vanni, S.; Nitti, C.; Kamphuisen, P.; Vedovati, M.C.; De Natale, M.G.; Konstantinides, S. Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model. Eur. Respir. J. 2016, 48, 780–786.
[26]	Konstantinides, S.V.; Meyer, G.; Becattini, C.; Bueno, H.; Geersing, G.J.; Harjola, V.P.; Huisman, M.V.; Humbert, M.; Jennings, C.S.; Jiménez, D.; Kucher, N.; Lang, I.M.; Lankeit, M.; Lorusso, R.; Mazzolai, L.; Meneveau, N.; Ní Áinle, F.; Prandoni, P.; Pruszczyk, P.; Righini, M.; Torbicki, A.; Van Belle, E.; Zamorano, J.L.; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur. Heart J. 2020, 41, 543–603.
[27]	Hobohm, L.; Hellenkamp, K.; Hasenfuß, G.; Münzel, T.; Konstantinides, S.; Lankeit, M. Comparison of risk assessment strategies for not-high-risk pulmonary embolism. Eur. Respir. J. 2016, 47, 1170–1178.
[28]	Folsom, A.R.; Cushman, M.; Tsai, M.Y.; Heckbert, S.R.; Aleksic, N. Prospective study of the G20210A polymorphism in the prothrombin gene, plasma prothrombin concentration, and incidence of venous thromboembolism. Am. J. Hematol. 2002, 71, 285–290.
[29]	Ridker, P.M.; Hennekens, C.H.; Miletich, J.P. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation. 1999, 99, 999–1004.
[30]	Mari, D.; Ogliari, G.; Castaldi, D.; Vitale, G.; Bollini, E.M.; Lio, D. Hemostasis and ageing. Immun. Ageing. 2008, 5, 12.
[31]	Walker, A.J.; Card, T.R.; West, J.; Crooks, C.; Grainge, M.J. Incidence of venous thromboembolism in patients with cancer–A cohort study using linked United Kingdom databases. Eur. J. Cancer. 2013, 49, 1404–1413.
[32]	Wun, T.; White, R.H. Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors. Cancer Invest. 2009, 27, 63–74.
[33]	Prandoni, P.; Lensing, A.W.; Büller, H.R.; Cogo, A.; Prins, M.H.; Cattelan, A.M.; Cuppini, S.; Noventa, F.; ten Cate, J.W. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N. Engl. J. Med. 1992, 327, 1128–1133.
[34]	Varga, Z.; Flammer, A.J.; Steiger, P.; Haberecker, M.; Andermatt, R.; Zinkernagel, A.S.; Mehra, M.R.; Schuepbach, R.A.; Ruschitzka, F.; Moch, H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020, 395, 1417–1418.
[35]	Tang, N.; Li, D.J.; Wang, X.; Sun, Z.Y. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost. 2020, 18, 844–847.
[36]	Lodigiani, C.; Iapichino, G.; Carenzo, L.; Cecconi, M.; Ferrazzi, P.; Sebastian, T.; Kucher, N.; Studt, J.D.; Sacco, C.; Bertuzzi, A.; Sandri, M.T.; Barco, S.; Humanitas COVID-19 Task Force. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb. Res. 2020, 191, 9–14.
[37]	Klok, F.A.; Kruip, M.J.H.A.; van der Meer, N.J.M.; Arbous, M.S.; Gommers, D.A.M.P.J.; Kant, K.M.; Kaptein, F.H.J.; van Paassen, J.; Stals, M.A.M.; Huisman, M.V.; Endeman, H. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb. Res. 2020, 191, 145–147.
[38]	Candeloro, M.; Di Nisio, M.; Potere, N.; Di Pizio, L.; Secinaro, E.; De Flaviis, C.; Federici, C.; Guglielmi, M.D.; Pardi, S.; Schulman, S.; Porreca, E. Frailty phenotype as a predictor of bleeding and mortality in ambulatory patients receiving direct oral anticoagulants. J. Am. Geriatr. Soc. 2022, 70, 3503–3512.
[39]	Coleman, C.I.; Turpie, A.G.G.; Bunz, T.J.; Beyer-Westendorf, J. Effectiveness and safety of rivaroxaban versus warfarin in frail patients with venous thromboembolism. Am. J. Med. 2018, 131, 933–938.e1.
[40]	Ho, P.; Brooy, B.L.; Hayes, L.; Lim, W.K. Direct oral anticoagulants in frail older adults: a geriatric perspective. Semin. Thromb. Hemost. 2015, 41, 389–394.
[41]	Pollack, C.V. Jr, Reilly, P.A.; Eikelboom, J.; Glund, S.; Verhamme, P.; Bernstein, R.A.; Dubiel, R.; Huisman, M.V.; Hylek, E.M.; Kamphuisen, P.W.; Kreuzer, J.; Levy, J.H.; Sellke, F.W.; Stangier, J.; Steiner, T.; Wang, B.S.; Kam, C.W.; Weitz, J.I. Idarucizumab for dabigatran reversal. N. Engl. J. Med. 2015, 373, 511–520.
[42]	Ferro, J.M.; Bousser, M.G.; Canhão, P.; Coutinho, J.M.; Crassard, I.; Dentali, F.; di Minno, M.; Maino, A.; Martinelli, I.; Masuhr, F.; de Sousa, D.A.; Stam, J.; Organization, E.S. European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis - endorsed by the European Academy of Neurology. Eur. J. Neurol. 2017, 24, 1203–1213.
[43]	Ferro, J.M.; Coutinho, J.M.; Dentali, F.; Kobayashi, A.; Alasheev, A.; Canhão, P.; Karpov, D.; Nagel, S.; Posthuma, L.; Roriz, J.M.; Caria, J.; Frässdorf, M.; Huisman, H.; Reilly, P.; Diener, H.C.; RE-SPECT CVT Study Group. Safety and efficacy of dabigatran etexilate vs dose-adjusted warfarin in patients with cerebral venous thrombosis: a randomized clinical trial. JAMA Neurol. 2019, 76, 1457–1465.
[44]	van de Munckhof, A.; van Kammen, M.S.; Krzywicka, K.; Aaron, S.; de Sousa, D.A.; Antochi, F.; Arauz, A.; Barboza, M.A.; Conforto, A.B.; Dentali, F.; Contreras, D.G.; Ji, X.M.; Jood, K.; Heldner, M.R.; Hernández-Pérez, M.; Kam, W.; Kleinig, T.J.; Kristoffersen, E.S.; Leker, R.R.; Lemmens, R.; Poli, S.; Yeşilot, N.; Wasay, M.; Wu, T.Y.; Arnold, M.; Lucas-Neto, L.; Middeldorp, S.; Putaala, J.; Tatlisumak, T.; Ferro, J.M.; Coutinho, J.M. Direct oral anticoagulants for the treatment of cerebral venous thrombosis - a protocol of an international phase IV study. Front. Neurol. 2023, 14, 1251581.
[45]	Sharma, M.; Cornelius, V.R.; Patel, J.P.; Davies, J.G.; Molokhia, M. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation. 2015, 132, 194–204.
[46]	Chaudhary, R.; Pagali, S.; Garg, J.; Murad, M.H.; Wysokinski, W.E.; McBane, R.D. 2nd. DOACs versus VKAs in older adults treated for acute venous thromboembolism: systematic review and meta-analysis. J. Am. Geriatr. Soc. 2020, 68, 2021–2026.
[47]	Poli, D.; Antonucci, E.; Bertù, L.; Vignini, E.; Ruocco, L.; Mastroiacovo, D.; Paparo, C.; Pastori, D.; Testa, S.; Ageno, W.; Palareti, G.; coordinator of START2 Register. Very elderly patients with venous thromboembolism on oral anticoagulation with VKAs or DOACs: Results from the prospective multicenter START2-Register Study. Thromb. Res. 2019, 183, 28–32.
[48]	Klok, F.A.; Kooiman, J.; Huisman, M.V.; Konstantinides, S.; Lankeit, M. Predicting anticoagulant-related bleeding in patients with venous thromboembolism: a clinically oriented review. Eur. Respir. J. 2015, 45, 201–210.
[49]	Kearon, C.; Akl, E.A.; Ornelas, J.; Blaivas, A.; Jimenez, D.; Bounameaux, H.; Huisman, M.; King, C.S.; Morris, T.A.; Sood, N.; Stevens, S.M.; Vintch, J.R.E.; Wells, P.; Woller, S.C.; Moores, L. Antithrombotic therapy for VTE disease CHEST guideline and expert panel report. Chest. 2016, 149, 315–352.
[50]	Xi, S.Z.; Liu, C.Y.; Yu, S.H.; Qiu, J.X.; He, S.B.; Yi, Z. Comparison of performances among four bleeding-prediction scores in elderly cancer patients with venous thromboembolism. Hämostaseologie. 2023, 43, 281–288.
[51]	Scherz, N.; Méan, M.; Limacher, A.; Righini, M.; Jaeger, K.; Beer, H.J.; Frauchiger, B.; Osterwalder, J.; Kucher, N.; Matter, C.M.; Banyai, M.; Angelillo-Scherrer, A.; Lämmle, B.; Husmann, M.; Egloff, M.; Aschwanden, M.; Bounameaux, H.; Cornuz, J.; Rodondi, N.; Aujesky, D. Prospective, multicenter validation of prediction scores for major bleeding in elderly patients with venous thromboembolism. J. Thromb. Haemost. 2013, 11, 435–443.
[52]	Schnegg‐Kaufmann, A.; Calzavarini, S.; Limacher, A.; Mean, M.; Righini, M.; Staub, D.; Beer, J.; Frauchiger, B.; Osterwalder, J.; Kucher, N.; Matter, C.M.; Husmann, M.; Banyai, M.; Aschwanden, M.; Mazzolai, L.; Hugli, O.; Nagler, M.; Daskalakis, M.; Rodondi, N.; Aujesky, D.; Angelillo‐Scherrer, A. A high Gas6 level in plasma predicts venous thromboembolism recurrence, major bleeding and mortality in the elderly: a prospective multicenter cohort study. J. Thromb. Haemost. 2019, 17, 306–318.
[53]	Muñoz, A.J.; Souto, J.C.; Lecumberri, R.; Obispo, B.; Sanchez, A.; Aparicio, J.; Aguayo, C.; Gutierrez, D.; Palomo, A.G.; Fanjul, V.; del Rio-Bermudez, C.; Viñuela-Benéitez, M.C.; Hernández-Presa, M.Á. Development of a predictive model of venous thromboembolism recurrence in anticoagulated cancer patients using machine learning. Thromb. Res. 2023, 228, 181–188.

基于CiteSpace和VOSviewer软件分析老年患者静脉血栓栓塞症的文献计量学分析

Bibliometric analysis of venous thromboembolism in the elderly using CiteSpace and VOSviewer

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 9

参考文献 53

相关文章 13

编辑推荐

Metrics

本文评价

[1]	邱秀梁, 蓝荫香. 关于余甘子的全球研究趋势: 1993年至2024年的文献计量与可视化分析[J]. 中国药学(英文版), 2026, 35(2): 173-186.
[2]	符青雷, 胡贝贝, 吴春兴. 用药咨询的研究现状及趋势: 基于文献计量学研究[J]. 中国药学(英文版), 2025, 34(4): 354-369.
[3]	王雨, 卢晓静, 岳向峰, 阚琳玮, 杜书章. 基于Web of Science的PCSK9抑制剂在心血管治疗领域相关研究文献计量学分析[J]. 中国药学(英文版), 2025, 34(3): 232-250.
[4]	陈铭瑜, 黄有琪, 邓金珠, 林宇齐, 高红瑾, 陈敏. 合并稳定性冠状动脉疾病对非瓣膜性房颤患者单一抗凝治疗的潜在影响: 一项倾向性评分匹配研究[J]. 中国药学(英文版), 2025, 34(11): 989-1002.
[5]	卢晓静, 贾雪冬, 司方莹, 杨晰, 张婉, 尹钊. 药师主导的老年患者干预研究: 一项文献计量学分析[J]. 中国药学(英文版), 2024, 33(8): 751-765.
[6]	朱愿超, 陈晨, 胡欣. 比阿培南在高龄老年患者中的应用[J]. 中国药学(英文版), 2023, 32(2): 145-152.
[7]	李方存, 张鼎, 李梓, 侯召猛, 陈炜, 陈洁, 胡跃强. 探索干细胞在阿尔茨海默病的研究前景: 2002–2021年文献计量分析[J]. 中国药学(英文版), 2023, 32(10): 813-834.
[8]	王壮飞, 管晓东, 周越, 韩晟, 姚鹏, 史录文. 中国中老年人自我药疗发生率及影响因素研究：基于CHARLS 2011年, 2013年和2015年的面板数据[J]. 中国药学(英文版), 2019, 28(6): 430-438.
[9]	杨思敏, 余四旺. 北京大学药学院举办癌症化学预防论坛[J]. 中国药学(英文版), 2016, 25(9): 704-706.
[10]	李方园, 张贵育, 欧日兰, 王莹, 戚笑笑, 刘中秋, 卢琳琳. 中草药对幽门螺旋杆菌导致的胃癌的预防作用[J]. 中国药学(英文版), 2016, 25(4): 250-265.
[11]	马婉婉, 唐叔南, 曹明楠, 葛泽梅, 李润涛, 余四旺. 氨基二硫代甲酸酯类化合物IC5抑制结直肠癌细胞增殖及干预炎症性肠病相关结直肠癌发展[J]. 中国药学(英文版), 2014, 23(9): 610-616.
[12]	阙琳玲, 王荟霞, 曹宝山, 杨晓达, 王夔, 余四旺^*. 转录因子Nrf2在癌症化学预防与化疗耐药性中的调控和功能[J]. , 2011, 20(1): 5-19.
[13]	许川雅^*, 吴新民, 蒋建渝, 卢炜. 国人老年患者靶控输注丙泊酚的群体药代动力学[J]. , 2005, 14(3): 154-161.